-
Sector Analysis
Cell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
Orthodontic Materials and Products Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Orthodontic Materials and Products Pipeline Market Report Overview Orthodontic materials and products are designed to correct teeth and jaws that are positioned improperly. The orthodontic materials and products pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It is...
-
Product Insights
NewHemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hemophilia A is an X-linked recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury, or in the case of severe hemophilia, spontaneous hemorrhage. Symptoms may include bleeding...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis,...
-
Product Insights
NewBiliary Tumor – Drugs In Development, 2024
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
-
Product Insights
NewHeart Valve Disease – Drugs In Development, 2024
Empower your strategies with our Heart Valve Disease – Drugs In Development, 2024 report and make more profitable business decisions. Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular...